Fixed-dose vs loose-dose combination antidiabetic therapy and cardiorenal outcomes in type 2 diabetes: a nationwide comparative effectiveness study
Main finding · Heart failureResult — go to the resultHazard ratio 0.88 95% CI 0.79–0.99Authors' conclusion
FDC therapy in people with type 2 diabetes was associated with a lower rate of heart failure, particularly in older adults. Higher medication adherence appeared to mediate nearly half of this association.
Study context
- Population
- Adults with T2D, Swedish national registers; matched cohort mean age 62 years, 67% malematched cohort
- Exposure
- Oral antidiabetic fixed-dose combination (FDC) vs loose-dose combination (LDC) therapy
- Outcome
- Cardiorenal outcomes: acute MI, AF, unstable angina, HF, ischaemic stroke, eGFR < 30 ml/min/1.73m2
- Follow-up
- Median 4.0 years (cardiovascular) and 3.8 years (kidney)
Methodological detailsnew-user, active-comparator, propensity score matching without replacement, Swedish national registers
- New-user
- Active-comparator
- Propensity score matching without replacement
- Swedish national registers
Main finding
Heart failure
Hazard ratio
0.88
95% CI 0.79–0.99
FDCvs LDC
HR 0.88 (95% CI 0.79–0.99)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Treatment adherence (proportion of days covered > 80%, first year)
| Outcome | HR (95% CI) | |
|---|---|---|
| Heart failure, aged ≥ 65 yearsLower rate with FDC | 0.79 (0.69–0.91) | |
| 0.512Hazard ratio (log scale) |
Mediation of HF association by adherence
- Proportion of HF association mediated by adherence
- 47%
Original publication
Fixed-dose vs loose-dose combination antidiabetic therapy and cardiorenal outcomes in type 2 diabetes: a nationwide comparative effectiveness study. Cardiovasc Diabetol. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →